Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016 Featuring 10 Leading Companies & Drug Profiles - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia Associated With Alzheimer's Disease and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Dementia Associated With Alzheimer's Disease Overview
3. Therapeutics Development
4. Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview
5. Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis
6. Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies
7. Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes
8. Dementia Associated With Alzheimer's Disease Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Dementia Associated With Alzheimer's Disease - Products under Development by Companies
13. Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes
14. Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development

• Adamas Pharmaceuticals, Inc.
• AgeneBio Inc.
• Amarantus Bioscience Holdings, Inc.
• Boehringer Ingelheim GmbH
• Chase Pharmaceuticals Corporation
• Eisai Co., Ltd.
• FORUM Pharmaceuticals Inc.
• H. Lundbeck A/S
• MediPost Co., Ltd.
• Neurodyn Inc.

For more information visit http://www.researchandmarkets.com/research/qv4kbr/dementia